Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

Siemens AG, Germany, intends to acquire US-based Dade Behring, Inc., by submitting a cash

offer to Dade Behringís shareholders. The companies have signed a merger agreement pursuant

to which Siemens shall commence the tender offer and the company board of Dade Behring

shall recommend that the shareholders tender their shares according to the offer.

- Siemens is a global, publicly listed, electrical engineering and electronics company, based in Germany. It focuses on seven core areas: Information & Communication, Automation & Control, Power, Transportation, Medical, Lighting, and Financing and Real Estate.

- The target undertaking, Dade Behring, is also publicly listed. The company develops, manufactures and markets in vitro diagnostic (IVD) systems for hospitals and clinical laboratories. Its activities comprise, inter alia, immunochemistry and clinical chemistry testing. Dade Behring is also active in the fields of haemostasis and microbiology.

The concentration will concern the area of IVD and, in particular, the field of

immunochemistry systems.